Klivira
Request demo

Optimizing Tezspire Prior Authorization for Gastroenterology Practices

Navigating Tezspire prior authorization for gastroenterology presents unique challenges, even when the drug's primary indications lie outside traditional GI pathways. Klivira provides a robust platform to manage complex biologic prior authorizations across all specialties, including the specific needs of gastroenterology practices.

Gastroenterology practices face a substantial prior authorization burden, particularly with high-volume categories like biologics, specialty drugs, and advanced procedures. While Tezspire is primarily indicated for severe asthma and eosinophilic conditions, the overarching complexities of biologic prior authorization remain consistent. Klivira's automation platform is designed to alleviate this administrative load, ensuring efficient processing for all complex PAs.

The Landscape of Biologic Prior Authorization in Gastroenterology

Gastroenterology is a high-volume specialty for prior authorizations, driven by the increasing use of biologics for chronic conditions like Inflammatory Bowel Disease (IBD). Managing prior authorization for biologics, including agents like Tezspire if encountered, requires meticulous attention to payer-specific criteria, clinical guidelines, and stringent documentation. Klivira streamlines this process, ensuring that all necessary information is accurately submitted to avoid delays and denials.

High-Volume Prior Authorization Categories in GI

  • IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors, JAK inhibitors, S1P modulators)
  • Hepatitis C direct-acting antivirals
  • Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
  • Endoscopic procedures with specific PA requirements (e.g., capsule endoscopy, ERCP, EUS)
  • Specialty drugs for functional GI disorders (e.g., eluxadoline, prucalopride, linaclotide)

Critical Documentation for Biologic Approvals in GI

For biologics commonly used in gastroenterology, such as those for IBD, payers consistently require comprehensive documentation aligned with guidelines from bodies like ACG, AGA, and AASLD. This includes diagnosis confirmation, disease severity assessment (e.g., Mayo score for UC, CDAI for Crohn's), evidence of prior conventional therapy trial, and necessary pre-initiation screenings like TB and hepatitis. Similar rigorous standards apply to any biologic, ensuring medical necessity is clearly established for approval.

Common Denial Reasons for Gastroenterology Prior Authorizations

  • Failure to meet step therapy requirements for IBD biologics (e.g., conventional therapy trial, TNF inhibitor trial before non-TNF agents, biosimilar first)
  • Inadequate documentation of disease severity (e.g., missing Mayo score, CDAI)
  • Gaps in screening documentation (e.g., TB, hepatitis screening pre-biologic initiation)
  • Fibrosis-stage documentation gaps or drug-drug interaction concerns for Hepatitis C DAAs
  • Clinical correlation gaps or insufficient prior workup for advanced imaging or capsule endoscopy requests

Klivira's Strategic Approach to GI Prior Authorization

Klivira's platform provides a targeted solution for the unique prior authorization challenges within gastroenterology. Our system incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologics, automates treatment-status classification from EMR medication histories, and manages periodic re-authorization workflows for chronic treatments. Furthermore, Klivira addresses the complexities of medical-vs-pharmacy benefit routing for biologic agents, ensuring appropriate submission channels regardless of administration mode changes.

Frequently asked questions

How does Klivira handle step therapy requirements for biologics in gastroenterology?

Klivira integrates ACG/AGA-guideline-aware step therapy logic into its platform, automating the verification of prior conventional therapy trials and ensuring compliance with payer-specific sequencing for IBD biologics. This minimizes denials related to step therapy non-adherence.

What documentation is critical for IBD biologic prior authorizations, and how does Klivira assist?

Critical documentation includes diagnosis confirmation, disease severity scores (e.g., Mayo score, CDAI), prior conventional therapy trial, and pre-initiation screenings like TB and hepatitis. Klivira automates the extraction and organization of this data from your EMR, ensuring comprehensive and accurate submissions.

Can Klivira manage re-authorizations for chronic GI conditions requiring ongoing biologic therapy?

Yes, Klivira's platform includes a dedicated workflow for periodic re-authorization of chronic-treatment biologics, common in IBD management. This proactively manages renewal cycles, prompting for updated documentation to ensure continuous coverage.

How does Klivira address the medical-vs-pharmacy benefit split for GI biologics?

Klivira's system is designed to handle the nuanced medical-vs-pharmacy benefit routing for biologic agents. It intelligently directs prior authorization requests to the correct payer channel based on the administration mode, adapting as a patient's treatment regimen or benefit structure evolves.

Does Klivira integrate with EMRs to pull relevant GI patient data for prior authorizations?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR, to seamlessly pull patient demographics, diagnoses, medication history, and clinical notes. This automation reduces manual data entry and improves the accuracy of prior authorization submissions for gastroenterology.

Related coverage

Other tezspire prior authorization by payer

Other tezspire prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo